Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Beograd, Serbia Clinical Trials

A listing of Beograd, Serbia clinical trials actively recruiting patients volunteers.

RESULTS

Found (25) clinical trials

Efficacy Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.

This is a Phase 2a, double-blind, placebo-controlled, parallel group study in subjects with active ulcerative colitis and a non-remission (partial) response to infliximab. All enrolled subjects must have been on infliximab for a minimum of 14 weeks with last dose 8 weeks prior to the date of randomization. Subjects will ...

Phase

374.88 miles

Learn More »

Lifestyle and Pharmacological Interventions in Hypertrophic Cardiomyopathy

Background and Rationale for the Study: Hypertrophic cardiomyopathy (HCM) is the most common hereditary cardiac disease, affecting one in 500 individuals. The predominant cause is mutation of genes that encode protein components of the cardiac sarcomere. The mechanisms that lead from a sarcomere gene mutation to phenotypic expression of HCM ...

Phase

42.01 miles

Learn More »

Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen

In Phase IIa, dose-escalation study to determine the optimum tolerated dose and a recommended Phase IIb (RPIIb) dose in combination with pembrolizumab in subjects with recurrent or metastatic squamous cell carcinoma of the head and neck who have failed platinum or a platinum containing regimen. In Phase IIb, randomized control ...

Phase

42.01 miles

Learn More »

Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands

This extension study will include participants up to 60 participants with acromegaly from Study NCT03548415. All participants will remain on the same dose from the previous study and receive IONIS GHR-LRx (SC) injection once every 28 days as add-on to SRL therapy for 53 weeks. At the end of 53 ...

Phase

76.06 miles

Learn More »

KPL-301 for Subjects With Giant Cell Arteritis

This Phase 2 randomized, double-blind, placebo-controlled proof of concept study will evaluate the efficacy and safety of mavrilimumab co-administered with a 26-week corticosteroid taper in subjects with GCA. The study will consist of a screening period (up to 6 weeks), a 26-week double-blind placebo-controlled period during which subjects will receive ...

Phase

228.46 miles

Learn More »

A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222

This study will evaluate the safety, tolerability, and efficacy of ABBV-3067 given alone and in combination with various doses of ABBV-2222 in adults with Cystic Fibrosis who are homozygous for the F508del mutation.

Phase

199.99 miles

Learn More »

The Persistence of Autoantibody Neutralisation by BC 007 in Patients With Chronic HFrEF and Autoantibodies Against the Beta1-Adrenergic Receptor

Primary objective is: To compare the efficacy of an intravenous (i.v.) infusion of BC 007 with an untreated control arm in removal of 1 AAb at month 12 in participants with chronic heart failure with reduced ejection fraction (HFrEF) Secondary objectives are: To evaluate the time to recurrence of 1 ...

Phase

Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis

This study is an open-label study aiming at evaluating the long-term safety and the efficacy profile of ABX464 given once a day (o.d) at 50 mg in subjects who have been previously enrolled in the ABX464-103 clinical study (induction study) and who are willing to continue their treatment. All subjects ...

Phase

70.97 miles

Learn More »

Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease

The purpose of the study is to assess the safety and efficacy of JNJ-64304500 in participants with moderately to severely active Crohn's disease.

Phase

76.06 miles

Learn More »

Study to Compare Oral PF-06651600 PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

The purpose of this study is to determine whether PF-06651600 and PF-06700841 are effective in treatment of moderate to severe ulcerative colitis.

Phase

6.49 miles

Learn More »